Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Xeris Pharmaceuticals Inc
XERS | US
6.71
USD0.47
7.53%
XERS | US
Loading StockChartView...
About Xeris Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/06/2026
Close
6.71
Open
6.52
High
7.00
Low
6.51
Xeris Biopharma Holdings Inc. a biopharmaceutical company engages in developing and commercializing therapies in Illinois. The company markets Gvoke a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis a therapy for the treatment of hyperkalemic hypokalemic and related variants of primary periodic paralysis; and Recorlev a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago Illinois.
View LessXERS | US
Risk
50.7
Sharpe
0.74
Luna's Score
60/100
Recommendation
Hold
Luna says (XERS | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
49.5%1 month
50.7%3 months
45.5%6 months
48.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.34
Debt to equity
-13.99
Debt to assets
0.81
Ent. to EBITDA
-3.36
Ent. to rev.
3.57
PEG
-
Other Fundamentals
EBITDA
-25.00M
MarketCap
999.78M
MarketCap(USD)
999.78M
Div. yield
-
Op. margin
-17.03
Erngs. growth
-
Rev. growth
26.50
Ret. on equity
-617.16
Short ratio
6.26
Short perc.
7.63
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.19
Range1M
1.19
Range3M
1.76
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.51
Price X volume
14.63M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.36 | 0.53 | Cheaper |
| Ent. to Revenue | 3.57 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.34 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 45.50 | 72.80 | Lower Risk |
| Debt to Equity | -13.99 | -1.23 | Cheaper |
| Debt to Assets | 0.81 | 0.25 | Expensive |
| Market Cap | 999.78M | 3.66B | Emerging |
